A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.
- Resource Type
- Article
- Source
- International Clinical Psychopharmacology; Mar2018, Vol. 33 Issue 2, p79-87, 9p
- Subject
- Language
- ISSN
- 02681315